Media Articles Related to Optison (Albumin Human)
Diagnostic tool identifies children with emotional behavior difficulties in South Africa
Source: HIV / AIDS News From Medical News Today [2014.04.16]
Research on children orphaned by HIV/AIDS in South Africa may provide insight on how to identify and help children with emotional behavior issues in other areas of the world, which may have limited...
Third Annual EU Device and Diagnostic Regulation Conference, June 12-13, 2014, Brussels
Source: Conferences News From Medical News Today [2014.04.03]
For the third straight year, Q1 Productions will host the EU Device and Diagnostic Regulation Conference, offering attendees an exclusive opportunity to participate in interactive discussions with...
New diagnostic test for bowel diseases
Source: Colorectal Cancer News From Medical News Today [2014.03.31]
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created by a group of researchers in the UK.
New diagnostic, treatment approach for aggressive prostate cancer suggested by cholesterol-metabolism study
Source: Cholesterol News From Medical News Today [2014.03.06]
Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new...
Diagnostic Errors Cause Up To 160,000 Deaths Annually, USA
Source: Litigation / Medical Malpractice News From Medical News Today [2013.04.24]
Researchers at Johns Hopkins have evaluated the extent of diagnostic errors in the U.S. They found that such errors account for around 160,000 deaths every year.
Published Studies Related to Optison (Albumin Human)
Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. [2011.07]
CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatinine ratio is independently associated with HbA1c and NT-proBNP, even in non-diabetic patients.
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). [2011.06]
BACKGROUND: The PREVEND IT investigated whether treatment targeted at lowering urinary albumin excretion (UAE) would reduce adverse cardiovascular events. We obtained extended follow-up data to approximately 10 years to investigate the long-term effects of fosinopril 20 mg and pravastatin 40 mg on cardiovascular outcomes in subjects with UAE >15 mg per 24 hours... CONCLUSIONS: Elevated UAE is associated with increased cardiovascular mortality and morbidity after 9.5 years of follow-up, with a doubling of the risk if the UAE is >50 mg per 24 hours. In this group, the benefits of 4-year treatment with fosinopril were sustained during posttrial follow-up for cardiovascular mortality and morbidity. We propose that UAE be used to estimate risk in the general population and that large clinical trials be designed to confirm the hypothesis that angiotensin-converting enzyme-inhibitor treatment may be beneficial in patients with mildly elevated UAE despite the absence of other comorbidities. Copyright (c) 2011 Mosby, Inc. All rights reserved.
The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis. [2011.06]
BACKGROUND AND PURPOSE: The Albumin in Acute Stroke (ALIAS) Part 2 Trial is directly testing whether 2 g/kg of 25% human albumin (ALB) administered intravenously within 5 hours of ischemic stroke onset results in improved clinical outcome. Recruitment into Part 1 of the ALIAS Trial was halted for safety reasons. ALIAS Part 2 is a new, reformulated trial with more-stringent exclusion criteria. Our aim was to explore the efficacy of ALB in the ALIAS Part 1 data and to assess the statistical assumptions underlying the ALIAS Part 2 Trial... CONCLUSIONS: Preliminary results from the ALIAS Part 1 suggest a trend toward a favorable primary outcome in subjects treated with ALB and support the validity of the statistical assumptions that underlie the ALIAS Part 2 Trial. The ALIAS Part 2 Trial will confirm or refute these results. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov/ALIAS. Unique identifier: NCT00235495.
Co-administration of albumin-furosemide in patients with the nephrotic syndrome. [2011.05]
Generalized edema is one of the most important complications in patients with nephrotic syndrome... Co-administration of albumin and furosemide increased the urine volume and sodium level, which is due to increase in the GFR as well as the diuretic effects of furosemide.
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. [2011.05]
CONCLUSIONS: Irbesartan treatment was not significantly more effective than placebo in reducing nucleic acid oxidation. The results indicate that DNA oxidation in diabetes patients is reduced by various components in the treatment of diabetes where glycemic control seems to be important and addition of angiotensin II receptor antagonists does not lead to any substantial additional reduction. Furthermore, the reductions in DNA oxidation and albumin excretion seem to be counteracted by smoking.
Clinical Trials Related to Optison (Albumin Human)
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure and Pulmonary Vascular Resistance [Recruiting]
Regadenoson Real Time Perfusion Imaging Trial-Optison [Recruiting]
The purpose if this study is to examine how effective Regadenoson is in detecting coronary
artery disease during a stress echocardiogram when Optison is administered. Optison is a
contrast agent that improves the images of the heart on the echocardiogram (echo) machine.
Optison is approved by the Food and Drug Administration (FDA) to use during stress
echocardiograms. Regadenoson is a commercially available rapid acting stress agent that is
used to chemically increase the heart rate and is approved for nuclear imaging tests.
Regadenoson is a FDA approved drug but not for the intended use in this study.
Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors [Suspended]
St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to
be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves
to create pictures, allowing doctors and other medical professionals to "see" inside the
Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's
Research Hospital researchers want to learn the best and safest dose of this ultrasound
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease [Recruiting]
The purpose of this study is to find the optimal dose from 3 different dose levels - 0. 15
mL, 0. 5 mL and 1. 5 mL of Optison in assessing the presence of disease of the carotid
arteries when comparing pre-contrast to post-contrast ultrasound (U/S) by dose group.
Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage [Not yet recruiting]
The investigators intend to determine if using Optison echocardiography contrast increases
sensitivity and specificity of detecting left atrial appendage thrombus in transesophageal
echocardiography studies as opposed to standard 2D and 3D TEE imaging without the use of